of extending the best quality of life possible; and
WHEREAS, One in eight women in the United States could be
diagnosed with invasive breast cancer in their lifetime; and
WHEREAS, In Pennsylvania, approximately 12,140 people are
expected to be diagnosed with breast cancer in 2018; and
WHEREAS, In the United States, it is estimated that more than
154,000 women have metastatic breast cancer; and
WHEREAS, In Pennsylvania, more than 1,800 people are expected
to die from breast cancer, nearly all from the metastatic stage
of the disease; and
WHEREAS, Although Caucasian women have the greatest incidence
of breast cancer, the mortality rate for African-American women
with breast cancer is higher and breast cancer is the leading
cause of cancer-related death in Hispanic women; and
WHEREAS, Breast cancer research should include everything
from screening through treatment and support of those with
metastatic breast cancer; and
WHEREAS, Metastatic breast cancer cuts short the lives of too
many people in Pennsylvania and leaves a lasting effect on their
families; and
WHEREAS, The economic burdens on the patient, family and
health care system are large; and
WHEREAS, While there have been advancements in the treatment
of metastatic breast cancer, many of those advancements have
benefited a small subset of patients; and
WHEREAS, Though it remains incurable, there is more research
to be done on metastatic breast cancer and this Commonwealth
continues to support critical research and advanced treatments
for metastatic breast cancer; therefore be it
RESOLVED, That the Senate designate October 13, 2018, as
20180SR0446PN2060 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30